Head to Head Review: CG Oncology (NASDAQ:CGON) versus Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV) and CG Oncology (NASDAQ:CGON) are both companies focused on the medical field, but which one stands out as a better investment? In this article, we will evaluate the two companies based on various factors including dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings, and risk.

Profitability

This section compares the profitability measures of Artiva Biotherapeutics and CG Oncology, specifically their net margins, return on equity, and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	N/A	N/A
CG Oncology	-10,642.98%	-18.97%	-15.36%

Analyst Ratings

The following are the current recommendations for Artiva Biotherapeutics and CG Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	0	0	5	0	3.00
CG Oncology	0	0	8	1	3.11

Currently, Artiva Biotherapeutics has a consensus target price of $21.25, indicating a potential upside of 68.52%. Meanwhile, CG Oncology's consensus target price is $63.88, suggesting a potential upside of 83.00%. This demonstrates that analysts view CG Oncology as a more advantageous investment.

Earnings and Valuation

This part compares the financial performance and valuation metrics of both companies, looking at gross revenue, earnings per share, and price-to-earnings ratio.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CG Oncology	$200,000.00	11,803.13	-$48.61 million	N/A	N/A

Artiva Biotherapeutics has reported higher earnings compared to its revenue, whereas CG Oncology has generated a small amount of revenue with significantly larger reported losses.

Insider & Institutional Ownership

CG Oncology has attracted 26.6% of institutional investors, providing a positive signal that large financial entities have confidence in the company's long-term potential.

Summary

Overall, CG Oncology outperforms Artiva Biotherapeutics in 6 out of 9 categories when the two stocks are compared.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to developing natural killer (NK) cell therapies aimed at treating autoimmune diseases and cancers. The flagship product in its pipeline is AB-101, an NK cell therapy designed for patients facing conditions like lupus nephritis and certain types of cancers. Furthermore, it is working on AB-201 and AB-205, which are also NK cell product candidates. The company was established in 2019 and is based in San Diego, California.

About CG Oncology

CG Oncology, Inc. specializes in oncolytic immunotherapy with a focus on creating innovative bladder-sparing treatments for bladder cancer patients. Its key development programs include BOND-003, CORE-001, and several others aimed at treating varying stages of bladder cancer. Founded in 2010 and based in Irvine, California, the company originally operated under the name Cold Genesys, Inc. before rebranding in 2020.

CGOncology, Artiva, Biotechnology, Investment, Profitability